Icon Plc (NASDAQ:ICLR) – Equities researchers at First Analysis issued their FY2017 earnings per share estimates for shares of Icon in a report released on Monday. First Analysis analyst T. Van. Fleet forecasts that the medical research company will earn $5.37 per share for the year. First Analysis also issued estimates for Icon’s Q4 2017 earnings at $1.41 EPS, Q1 2018 earnings at $1.36 EPS, Q2 2018 earnings at $1.49 EPS and FY2018 earnings at $5.95 EPS.
Several other equities analysts have also issued reports on the stock. KeyCorp reissued an “overweight” rating and set a $125.00 price objective (up from $115.00) on shares of Icon in a report on Monday, November 13th. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Icon from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. SunTrust Banks reissued a “buy” rating and set a $138.00 price objective on shares of Icon in a report on Sunday, October 29th. Barclays lifted their price objective on shares of Icon from $108.00 to $120.00 and gave the company an “equal weight” rating in a report on Friday, October 27th. Finally, Credit Suisse Group reissued an “outperform” rating and set a $120.00 price objective (up from $105.00) on shares of Icon in a report on Monday, October 16th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $121.00.
Icon (NASDAQ ICLR) opened at $113.52 on Wednesday. The stock has a market cap of $6,166.29, a P/E ratio of 21.86, a P/E/G ratio of 1.76 and a beta of 0.56. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90. Icon has a 1-year low of $73.76 and a 1-year high of $124.48.
Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.03. The company had revenue of $440.30 million for the quarter, compared to analyst estimates of $438.09 million. Icon had a net margin of 16.37% and a return on equity of 28.42%. Icon’s revenue was up 4.8% compared to the same quarter last year. During the same period last year, the company posted $1.19 earnings per share.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acrospire Investment Management LLC grew its holdings in Icon by 20.1% in the second quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after purchasing an additional 200 shares during the last quarter. Parallel Advisors LLC grew its holdings in Icon by 20.7% in the second quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock worth $133,000 after purchasing an additional 217 shares during the last quarter. SG Americas Securities LLC purchased a new position in Icon in the third quarter worth $148,000. Sheaff Brock Investment Advisors LLC purchased a new position in Icon in the second quarter worth $208,000. Finally, Commonwealth Equity Services Inc purchased a new position in Icon in the third quarter worth $208,000. 89.95% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Icon Plc (ICLR) Expected to Earn FY2017 Earnings of $5.37 Per Share” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://ledgergazette.com/2017/12/15/icon-plc-iclr-expected-to-earn-fy2017-earnings-of-5-37-per-share.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.